Hypoxic status in ovarian serous and mucinous tumors: Relationship between histological characteristics and HIF-1α/GLUT-1 expression

Archives of Gynecology and Obstetrics

Volumn 277, Issue 6, 2008, Pages 539-546

  Iida, Tetsuji ^a   Yasuda, Masanori ^b   Miyazawa, Masaki ^a   Fujita, Mariko ^a   Osamura, R Yoshiyuki ^a   Hirasawa, Takeshi ^a   Muramatsu, Toshinari ^a   Murakami, Masaru ^a   Saito, Kaoru ^c   Mikami, Mikio ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

GLUT 1; HIF 1 ; Mucinous tumor; Ovary; Serous tumor

Indexed keywords

BIOLOGICAL MARKER; DNA; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA;

ADENOMA; ADULT; AGED; ARTICLE; BINDING ASSAY; COMPARATIVE STUDY; CONTROLLED STUDY; DNA BINDING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MUCINOUS CARCINOMA; OVARY ADENOCARCINOMA; OVARY TUMOR; PROTEIN EXPRESSION; SEROMA;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; RNA, MESSENGER;

EID: 42649141679     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00404-007-0500-8     Document Type: Article

References (38)

1. Semenza GL (2002) HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 8:62-67
2. 2-dependent degradation domain via the ubiquitine-proteasome pathway. Proc Natl Acad Sci USA 95:7987-7992
3. 2 tension. Am J Physiol 271:1172-1180
4. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ (1999) The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275
5. Haber RS, Ranthan A, Weiser KR, Pritsker A, Itzkowitz SH, Bodian C, Slater G, Weiss A, Burstein DE (1998) GLUT-1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer 83:34-40
6. Wheeler TJ, Hinkle PC (1985) The glucose transporter of mammalian cells. Annu Rev Physiol 47:503-517
7. Medina RA, Owen GI (2002) Glucose transporters: expression, regulation and cancer. Biol Res 35:9-26
8. Wang BY, Kalir T, Sabo E, Sherman DE, Cohen C, Burstein DE (2000) Immunohistochemical staining of GLUT1 in benign, hyperplastic, and malignant endometrial epithelia. Cancer 88:2774-2781
9. Froehner SC, Davies A, Baldwin SA, Leinhard GE (1998) The blood-nerve barrier is rich in glucose transporter. J Neurocytol 17:173-178
10. Pardridge WM, Boado RJ, Farrell CR (1990) Brain-type glucose transporter (GLUT-1) is selectively localized to the blood-brain barrier: studies with quantitative western blotting and in situ hybridization. J Biol Chem 265:18035-18040
11. Agus DB, Gambhir SS, Pardridge WM, Spielholz C, Baselga J, Vera JC, Golde DW (1997) Vitamin C crosses the blood-brain barrier in the oxidized from through the glucose transporters. J Clin Invest 100:2842-2848
12. Younes M, Lechago LV, Lechago J (1996) Overexpression of the human erythrocyte glucose transporter occurs as a late event in human colorectal carcinogenesis and is associated with an increased incidence of lymph node metastases. Clin Cancer Res 2:1151-1154
13. Ogawa J, Inoue H, Koide S (1997) Glucose-transporter-type-I-gene amplification correlates with sialyl-Lewis-X synthesis and proliferation in lung cancer. Int J Cancer 74:189-192
14. Haber RS, Weiser KR, Pritsker A, Reder I, Burstein DE (1997) GLUT-1 glucose transporter expression in benign and malignant thyroid nodules. Thyroid 7:363-367
15. Lambert DW, Wool IS, Ellis A, Shirazi-Beechey SP (2002) Molecular changes in the expression of human colonic nutrient transporters during the transition from normality to malignancy. Br J Cancer 86:1262-1269
16. Yasuda M, Ogane N, Hayashi H, Kameda Y, Miyagi Y, Iida T, Mori Y, Tsukinoki K, Minematsu T, Osamura Y (2005) Glucose transporter-1 expression in the thyroid gland: clinicopathological significance for papillary carcinoma. Oncol Rep 14:1499-1504
17. Kalir T, Wang BY, Goldfischer M, Haber RS, Reder I, Demopoulos R, Cohen CJ, Burstein DE (2002) Immunohistochemical staining of GLUT-1 in benign, borderline, and malignant ovarian epithelia. Cancer 94:1078-1102
18. Cantuaria G, Fagotti A, Ferrandina G, Magalhaes A, Nadji M, Angioli R, Penalver M, Mancuso S, Scambia G (2001) GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer 92:1144-1150
19. Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G (2001) Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 7:1661-1668
20. Osada R, Horiuchi A, Kikuchi N, Yoshida J, Hayashi A, Ota M, Katsuyama Y, Mellilo G, Konishi I (2007) Expressions of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma. Hum Pathol 38:1310-1320
21. Wong C, Wellman TL, Lounsbury KM (2003) VEGF and HIF-1alpha expression are increased in advanced stages of epithelial ovarian cancer. Gynecol Oncol 91:513-517
22. Shweiki D, Itin A, Soffer D, Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843-845
23. Kimbro KS, Simons JW (2006) Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer 13:739-749
24. Treeck O, Wackwitz B, Haus U, Ortmann O (2006) Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol Oncol 102:292-299
25. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their matastases. Cancer Res 59:5830-5835
26. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL (2000) Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88:2606-2618
27. Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, van der Wall E (2001) Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 93:309-314
28. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G (2000) Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 60:4693-4696
29. Koukourakis MI, Giatromanolaki A, Skarlatos J, Corti L, Blandamura S, Piazza M, Gatter KC, Harris AL (2001) Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res 61:1830-1832
30. Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, Semenza GL (2001) Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61:2911-2916
31. Nishioka T, Oda Y, Seino Y, Yamamoto T, Inagaki N, Yano H, Imura H, Shigemoto R, Kikuchi H (1992) Distribution of the glucose transporters in human brain tumors. Cancer Res 52:3972-3979
32. Brown RS, Wahl RL (1993) Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 72:2979-2985
33. Mellanen P, Minn H, Grenman R, Harkonen P (1994) Expression of glucose transporters in head- and-neck tumors. Int J Cancer 56:622-629
34. Nagase Y, Takata K, Moriyama N, Aso Y, Murakami T, Hirano H (1995) Immunohistochemical localization of glucose transporters in human renal cell carcinoma. J Urol 153:798-801
35. Kawamura T, Kusakabe T, Sugino T, Watanabe K, Fukuda T, Nashimoto A, Honma K, Suzuki T (2001) Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer 92:634-641
36. Cantuaria G, Magalhaes A, Penalver M, Angioli R, Braunschweiger P, Gomez-Marin O, Kanhoush R, Gomez-Fernandez C, Nadji M (2000) Expression of GLUT-1 glucose transporter in borderline and malignant epithelial tumors of the ovary. Gynecol Oncol 79:33-37
37. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT (2002) Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22:7004-7014
38. Noguchi Y, Saito A, Miyagi Y, Yamanaka S, Marat D, Doi C, Yoshikawa T, Tsuburaya A, Ito T, Satoh S (2000) Suppression of facilitative glucose transporter 1 mRNA can suppress tumor growth. Cancer Lett 154:175-182